Kapicioğlu S, Cihanyurdu N, Cilingir H, Baki A H, Dinç H, Tuncer C
Section of Gastroenterology, Department of Internal Medicine, Karadeniz (Black Sea) Technical University School of Medicine, 61080, Trabzon, Turkey.
Eur J Ultrasound. 2000 Dec;12(2):95-101. doi: 10.1016/s0929-8266(00)00107-5.
Cisapride, a benzimide derivative, is a gastrointestinal prokinetic agent without dopamine-antagonistic or cholinomimetic effects. This study aims at assessing the effect of cisapride oral administration on portal flow in patients with advanced post hepatitic cirrhosis using duplex Doppler ultrasound (US).
A total of 12 patients with post-hepatitic liver cirrhosis were included in the study. Duplex Doppler sonographic examinations were performed before and after treatment. The subjects received 10 mg cisapride before starting the measurement procedure and then three times a day for 2 days. Portal haemodynamics including vessel diameters (mm), mean flow velocities (cm/s), blood flows (ml/min) were investigated.
Mean portal vein diameters, mean portal flow velocity and portal blood flow volume showed decreases of 18.6, 22.1 and 43.6% (P<0.001), respectively. After cisapride administration the portal vein diameter did not change in two patients and the portal vein velocity did not change in three patients. No significant change was found in systolic blood pressure, diastolic blood pressure or pulse rate after the administration of cisapride.
In this study, it was demonstrated that oral administration of cisapride results in a significant reduction of portal blood flow but there were no changes in heart rate or systolic pressure in patients with cirrhosis of the liver.
西沙必利是一种苯并咪唑衍生物，是一种无多巴胺拮抗或拟胆碱作用的胃肠促动力剂。本研究旨在使用双功多普勒超声（US）评估西沙必利口服给药对晚期肝炎后肝硬化患者门静脉血流的影响。
本研究共纳入12例肝炎后肝硬化患者。在治疗前后进行双功多普勒超声检查。受试者在开始测量程序前接受10mg西沙必利，然后每天三次，共2天。研究门静脉血流动力学，包括血管直径（mm）、平均流速（cm/s）、血流量（ml/min）。
门静脉平均直径、门静脉平均流速和门静脉血流量分别下降了18.6%、22.1%和43.6%（P<0.001）。服用西沙必利后，2例患者门静脉直径未改变，3例患者门静脉流速未改变。服用西沙必利后收缩压、舒张压或脉搏率无显著变化。
在本研究中，已证明口服西沙必利可导致门静脉血流量显著减少，但肝硬化患者的心率或收缩压无变化。
